HDFC Pharma And Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹22.49+0.35%
07 Sept 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for HDFC Pharma And Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (27.4%)
Mid Cap (37.5%)
Small Cap (35.1%)
Historical Asset Allocation
| Asset | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 |
|---|---|---|---|---|---|---|
| Equity | 99.53% | 97.25% | 98.68% | 97.30% | 98.52% | 98.22% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 0.47% | 2.75% | 1.32% | 2.70% | 1.48% | 1.78% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
38
P/E Ratio
48.41
P/B Ratio
6.32
Top Holding %
9.66%
Top 5 Holdings %
32.99%
Top 10 Holdings %
51.84%
AUM
₹2,940 Cr
Expense Ratio
1.08%
Since Inception
31.87%
Max Drawdown
-0.15%
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 14,26,049 | 283.86 | 9.66% | -0.30%↓ |
| Divis Laboratories Ltd. | Healthcare | 3,33,687 | 268.82 | 9.14% | 1.98%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 12,88,696 | 141.56 | 4.82% | -0.75%↓ |
| Aster DM Quality Care Ltd. | Healthcare | 16,81,027 | 138.21 | 4.70% | -0.35%↓ |
| Lupin Ltd. | Healthcare | 5,68,274 | 137.24 | 4.67% | -0.59%↓ |
| Cipla Ltd. | Healthcare | 9,25,035 | 136.28 | 4.64% | -0.55%↓ |
| Alkem Laboratories Ltd. | Healthcare | 1,87,494 | 107.84 | 3.67% | -0.33%↓ |
| Acutaas Chemicals Ltd. | Healthcare | 3,39,010 | 105.26 | 3.58% | -1.00%↓ |
| Anthem Biosciences Ltd. | Healthcare | 12,91,629 | 104.52 | 3.56% | -0.25%↓ |
| Neuland Laboratories Ltd. | Healthcare | 52,504 | 99.98 | 3.40% | 0.47%↑ |
| Ipca Laboratories Ltd. | Healthcare | 5,41,736 | 94.68 | 3.22% | -0.31%↓ |
| Global Health Ltd. | Healthcare | 6,37,841 | 89.65 | 3.05% | -0.03%↓ |
| Fortis Healthcare Ltd. | Healthcare | 8,66,882 | 81.92 | 2.79% | -0.39%↓ |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 9,84,676 | 79.24 | 2.70% | -0.37%↓ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3,40,887 | 76.15 | 2.59% | -0.29%↓ |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 21,75,025 | 72.1 | 2.45% | - |
| Torrent Pharmaceuticals Ltd. | Healthcare | 1,31,000 | 67.11 | 2.28% | - |
| Shilpa Medicare Ltd. | Healthcare | 10,80,751 | 66.06 | 2.25% | -0.23%↓ |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 4,88,093 | 65.62 | 2.23% | -0.30%↓ |
| Metropolis Healthcare Ltd. | Healthcare | 10,81,488 | 62.99 | 2.14% | -0.10%↓ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 99.53% | 97.25% | 98.68% | 97.30% | 98.52% | 98.22% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
24.8 / 100
Weighted average Value score is 24.8. This indicates that portfolio is relatively overvalued using composite of value measures.
Price Momentum score
74.5 / 100
Weighted average Price Momentum score is 74.5. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
86.7 / 100
Weighted average Quality score is 86.7. This indicates that portfolio has high quality using composite of quality measures.
QVM score
72.5 / 100
Weighted average QVM score is 72.5. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of HDFC Pharma And Healthcare Fund Direct-Growth?
The top holdings of HDFC Pharma And Healthcare Fund Direct-Growth as of 31 Jul 2026 are Sun Pharmaceutical Industries Ltd. (9.66%), Divis Laboratories Ltd. (9.14%), Max Healthcare Institute Ltd. (4.82%), Aster DM Quality Care Ltd. (4.70%), Lupin Ltd. (4.67%). These top 5 stocks together account for 32.99% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does HDFC Pharma And Healthcare Fund Direct-Growth hold in its portfolio?
HDFC Pharma And Healthcare Fund Direct-Growth holds 38 stocks in its portfolio as of 31 Jul 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of HDFC Pharma And Healthcare Fund Direct-Growth?
As of 31 Jul 2026, HDFC Pharma And Healthcare Fund Direct-Growth's top sector allocations are Healthcare (99.53%). You can find detailed sector allocation above.
What is the equity and debt allocation of HDFC Pharma And Healthcare Fund Direct-Growth?
As of 31 Jul 2026, HDFC Pharma And Healthcare Fund Direct-Growth has 99.53% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of HDFC Pharma And Healthcare Fund Direct-Growth?
As of 31 Jul 2026, HDFC Pharma And Healthcare Fund Direct-Growth's market cap allocation is 27.43% in large caps, 37.51% in mid caps, and 35.06% in small caps.
What is the PE ratio of HDFC Pharma And Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of HDFC Pharma And Healthcare Fund Direct-Growth is 48.41 as of 31 Jul 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of HDFC Pharma And Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for HDFC Pharma And Healthcare Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for HDFC Pharma And Healthcare Fund Direct-Growth?
The latest portfolio disclosure for HDFC Pharma And Healthcare Fund Direct-Growth is as of 31 Jul 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.